Could you please elaborate Captain? I don't really follow this...

Could you please elaborate Captain? I don't really follow this argument.

IMO the great strength of the DEP technology from an economic point of view (and assuming it lives up to our very high expectations) is that it may allow big pharma (AZ, Roche, Merck etc...) to re-invent some of their most successful oncology therapies which are, or soon will be, off patent, and get fresh patent protection for new and much improved DEP versions of them. On top of this we know that it is being coupled with at least one new experimental drug. So the commercial opportunity for SPL is quite extraordinary. BTW, where are the Phase 1 results for DEP/ Docetaxel ? They are a very long time coming!